Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Press Releases
Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022
NK cells derived from genetically engineered human induced pluripotent stem cells (iPSCs) hold great potential to become the next generation allogeneic cell therapy products.
1 / 3
Press Releases
Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing. Funds to Advance Pipeline of Novel Cell and Organ Therapies
Qihan Biotech Co. Ltd announced today that it has raised an additional $67 million in Series A++ financing. With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.
1 / 3
Press Releases
Qihan Biotech Publishes First Clinical Xenotransplantation Prototype, ‘Pig 3.0’, in Nature Biomedical Engineering
In a leap forward for immune privileged cell and organ therapy, researchers create first clinical xenotransplantation prototype with enhanced human immune compatibility and without active porcine endogenous retrovirus (PERV).
1 / 3
Join Our Team
Contact Us
Hangzhou Qihan Biotech Co., Ltd.
Address: Xiaoshan District, Hangzhou, Zhejiang, China
Zipcode: 311231
TEL: 0571-83500380
FAX: 0571-83500370